Radioligand Therapy Market 2025-2033: Pioneering Cancer Treatments, Major Acquisitions & Investment Highlights

Radioligand Therapy Market reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033, growing at a CAGR of 21.9% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Radioligand Therapy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/radioligand-therapy-market?oppratik

Mergers and Acquisitions

In December 2023, a major pharmaceutical company completed its acquisition of a radiopharmaceutical firm for approximately USD 1.4 billion, gaining access to late-stage radioligand therapy candidates targeting prostate cancer and neuroendocrine tumors.

In June 2024, a global pharmaceutical giant finalized its acquisition of a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates for USD 2 billion upfront, with an additional contingent payment of up to USD 400 million upon achieving regulatory milestones. The deal brought advanced actinium-based radioligand programs and manufacturing capabilities.

In June 2025, a subsidiary of a leading pharmaceutical company announced a USD 50 million expansion of its radioligand therapy research and development facilities, nearly doubling its operational footprint to accelerate next-generation RLT drug discovery

Latest Market News

The global radioligand therapy market was valued at USD 3.15 billion in 2025 and is projected to reach USD 10.91 billion by 2035, growing at a CAGR of 13.2 percent. Growth is driven by increasing regulatory approvals, manufacturing scale-up for isotopes like Lutetium-177, and rising adoption of PSMA and SSTR PET imaging for patient selection.

The Asia-Pacific region is expected to grow at the highest rate during the forecast period, attributed to expanding infrastructure, rising cancer incidence, and increasing clinical trial activities.

In June 2025, a leading analytics firm released a report identifying six radioligand therapy innovators as companies to watch, highlighting advances in alpha-emitting isotopes, combination therapies, and manufacturing capabilities.

Industry consolidation continues, with leading pharmaceutical companies commanding an estimated 95 to 98 percent of the global radioligand therapy market share through strategic investments, regulatory advancements, and extensive partnerships.

Supply chain challenges remain, particularly isotope scarcity for Lutetium-177 and Actinium-225, which may constrain market growth despite strong clinical demand.

Key Players:

Eli Lilly and Company., Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Oranomed, Sanofi, RadioMedix, Inc., Clarity Pharmaceuticals, Ariceum Therapeutics, and Blue Earth Therapeutics, among others

Growth Forecast Projected:

The Global Radioligand Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Radioligand Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?oppratik

Investments & Financial Developments:

In July 2025, a radiopharmaceutical biotech company raised USD 75.5 million in an oversubscribed Series A financing round. The funding will support clinical development of its lead fibroblast activation protein-targeting radioligand therapy candidate and expand its proprietary discovery platform.

Several major pharmaceutical companies have significantly increased their investments in radioligand therapy infrastructure and R&D throughout 2024 and 2025, reflecting strong industry confidence in this therapeutic modality.

Market Segmentation:

By Type: Lutetium Lu-177, Radium Ra 223 Dichloride, Others

By Target: Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR)

By Application: Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), Others

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Radioligand Therapy producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Radioligand Therapy revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/radioligand-therapy-market?oppratik

Product Launches and Clinical Developments:

In March 2025, regulatory authorities approved an expanded indication for a PSMA-targeted radioligand therapy, allowing its use earlier in the treatment pathway for patients with metastatic castration-resistant prostate cancer who have received androgen receptor pathway inhibitor therapy.

In August 2025, a company reported positive Phase 2 trial results for its radioligand therapy targeting specific tumor markers, demonstrating promising response rates in difficult-to-treat cancers.

In September 2025, researchers presented clinical trial results showing that patients with recurrent prostate cancer treated with PSMA-targeted radioligand therapy before radiotherapy experienced more than twice the progression-free survival compared to radiotherapy alone-17.6 months versus 7.4 months.

In October 2025, a clinical-stage company announced promising trial results for a novel lead-212-based PSMA-targeted alpha therapy for prostate cancer at a major oncology conference.

FAQ's

Q1: What is the current size of the Radioligand Therapy Market?

A: The Radioligand Therapy Market stood at US$ 2.41 billion in 2024 and is set to experience remarkable growth, reaching US$ 2.41 billion in 2024

Q2: How fast is the Radioligand Therapy Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 21.9% from 2025 to 2033

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.